Table 3.
Associations of statin use with late-stage breast cancer
| Comparison | Model type | HR | 95 % CI | p value |
|---|---|---|---|---|
| Baseline statin: yes versus no | Univariable | 0.87 | (0.71, 1.06) | 0.163 |
| Multivariablea | 0.93 | (0.76, 1.14) | 0.494 | |
| Baseline statin: by typeb | Univariable | |||
| Lipophilic versus none | 0.85 | (0.68, 1.07) | 0.158 | |
| Hydrophilic versus none | 0.93 | (0.63, 1.37) | 0.722 | |
| Lipophilic versus hydrophilic | Multivariable | 0.91 | (0.59, 1.42) | 0.686 |
| Lipophilic versus none | 0.92 | (0.73, 1.16) | 0.486 | |
| Hydrophilic versus none | 0.97 | (0.64, 1.45) | 0.868 | |
| Lipophilic versus hydrophilic | 0.95 | (0.50, 1.51) | 0.841 | |
| Statin use over time: yes versus no | Univariable | 0.83 | (0.69, 0.99) | 0.037 |
| Multivariablea | 0.84 | (0.70, 1.02) | 0.082 | |
| Statin use over time: by typeb | Univariable | |||
| Lipophilic versus none | 0.80 | (0.65, 0.97) | 0.022 | |
| Hydrophilic versus none | 0.96 | (0.65, 1.43) | 0.845 | |
| Unclassified versus none | 1.48 | (0.61, 3.57) | 0.381 | |
| Lipophilic versus hydrophilic | Multivariablea | 0.83 | (0.54, 1.28) | 0.390 |
| Lipophilic versus none | 0.80 | (0.64, 0.98) | 0.035 | |
| Hydrophilic versus none | 1.06 | (0.70, 1.59) | 0.784 | |
| Unclassified versus none | 1.57 | (0.65, 3.78) | 0.320 | |
| Lipophilic versus hydrophilic | 0.75 | (0.48, 1.17) | 0.210 |
Adjusted for race (American Indian or Alaskan Native; Asian or Pacific Islander; Black or African–American; Hispanic/Latino; White), education (none to some HS; HS diploma/GED; vocational, training school, some college or associate degree; college degree or more), smoking (never smoked; past smoker; current smoker), BMI (<25; 25–29; ≥30), waist circumference (≤88 cm;>88 cm), mammogram in the past 2 years (no; yes), Gail 5-year risk (<1.67 %; ≥1.67 %), female relative with breast cancer(no; yes), age at menarche (≤11, 12–13; 14+), number of live births (never pregnant; none; 1–2; 3+), breast biopsy (no; yes), hysterectomy (no; yes), hormone use (never; past user; current user <5 years; current user 5 to <10 years; current user ≥10 years), oral contraceptive (no; yes), aspirin use (no; yes) and study component (observational study; estrogen alone clinical trial, estrogen + progesterone clinical trial; dietary modification clinical trial; estrogen/estrogen + progesterone and dietary modification clinical trial)
Lipophilic (lovastatin, simvastatin, fluvastatin, atorvastatin), hydrophilic (pravastatin)